Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P47 in Rheumatoid Arthritis
NCT05489224Phase 3Completed
- Sponsor
- Celltrion
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Celltrion. Started Sep 2022; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05489224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05489224.